Page 3 - Metacrine Company Profile News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Metacrine company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Metacrine Company Profile Today - Breaking & Trending Today

METACRINE : UPDATES IBD CLINICAL DEVELOPMENT STRATEGY AND IMPLEMENTS RESTRUCTURING PLAN - Form 8-K

METACRINE UPDATES IBD CLINICAL DEVELOPMENT STRATEGY AND IMPLEMENTS RESTRUCTURING PLAN


- U.S. FDA clears IND to evaluate MET642 for the treatment of ulcerative colitis


. | February 11, 2022 ....

Preston Klassen , Exchange Commission , Drug Administration , Metacrine Inc , Private Securities Litigation Reform Act , Quarterly Report , Nc Stock Exchange , Press Release , Lcerative Mtcr Us59101e1038 ,

Metacrine to Present at 2021 Jefferies Healthcare Conference

SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the 2021 Jefferies Healthcare Conference at 11:00 a.m. ET on Friday, June 4, 2021. A live webcast of the presentation will be available at https://investors.metacrine.com/events-and-presentations. A replay of the webcast will be archived for 30 days following the conference. About Metacrine Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated an improved therapeutic profile in clinical trials. The Company’s two product candidates ....

Gastrointestinal Diseases , Jefferies Healthcare Conference , Clinical Trials , Iopharmaceutical Company , Preston Klassen , இரைப்பை குடல் நோய்கள் ,

Metacrine to Present at SVB Leerink 10th Annual Global Healthcare Conference


Metacrine to Present at SVB Leerink 10th Annual Global Healthcare Conference
February 19, 2021 06:30 ET
| Source:
Metacrine, Inc.
Metacrine, Inc.
San Diego, California, UNITED STATES
SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine, will present at the SVB Leerink 10th Annual Global Healthcare Conference on Friday, February 26, 2021 at 4:20 p.m. ET.
The live webcast will be available in the investor section of the company s website at www.metacrine.com. The webcast will be archived for 60 days following the presentation. ....

Preston Klassen , Chelcie Lister , Strategic Communications , Metacrine Inc , Annual Global Healthcare Conference , Nasdaq Mtcr , ப்ரெஸ்டந் கிளாசென் , மூலோபாய தகவல்தொடர்புகள் , ஆண்டு உலகளாவிய சுகாதாரம் மாநாடு ,

Metacrine Announces Publication of MET409 NASH Proof-of-Concept Study Results in the Journal of Hepatology

Publication highlights the first clinical evidence that the risk-benefit profile of FXR agonists can be enhanced through structural optimizationSAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the Journal of Hepatology has published the results from the company’s 12-week, randomized, placebo-controlled Phase 1b study of MET409, the company’s lead farnesoid X receptor (FXR) agonist, in patients with non-alcoholic steatohepatitis (NASH). “The publication of our Phase 1b study data in this highly regarded, peer-reviewed journal further underscores the promise of an optimized FXR to treat patients with NASH, a potentially life-threatening liver disease with no approved treatments,” said Hubert C. Chen, M.D., chief medical officer of Metacrine. “MET40 ....

Journal Of Hepatology , Non Alcoholic Steatohepatitis , Combination Therapies , Liver Disease , Clinical Trials , இதழ் ஆஃப் ஹெபடாலஜி , சேர்க்கை சிகிச்சைகள் , கல்லீரல் நோய் , மருத்துவ சோதனைகள் ,

Metacrine Announces FDA Fast Track Designation for MET642 as a Treatment of NASH

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to MET642, the company’s second farnesoid X receptor (FXR) agonist, for the treatment of non-alcoholic steatohepatitis (NASH). “We are pleased to have received a second fast track designation for product candidates from our proprietary FXR platform and believe this further demonstrates the recognition of significant unmet needs in patients with NASH by regulatory authorities,” said Hubert C. Chen, M.D., chief medical officer of Metacrine. “Given our recently reported, favorable Phase 1 data for MET642, we are excited about its potential and look forward to advancing it into the Phase 2a study in the first half of this year.& ....

Biopharmaceutical Company , Clinical Trial , Gastrointestinal Diseases , Fast Track Designation , Product Candidates , Forward Looking Statements , மருத்துவ சோதனை , இரைப்பை குடல் நோய்கள் , வேகமாக டிராக் பதவி , ப்ராடக்ட் வேட்பாளர்கள் , முன்னோக்கி பார்க்கிறது அறிக்கைகள் ,